Cancer Research Meeting Calendar Jordan
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 4334-4342, September 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Engbrecht, B. W.
Right arrow Articles by Fraker, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Engbrecht, B. W.
Right arrow Articles by Fraker, D. L.
[Cancer Research 59, 4334-4342, September 1, 1999]
© 1999 American Association for Cancer Research

Experimental Therapeutics

Photofrin-mediated Photodynamic Therapy Induces Vascular Occlusion and Apoptosis in a Human Sarcoma Xenograft Model1

Brett W. Engbrecht2, Chandrakala Menon2, Alexander V. Kachur, Stephen M. Hahn and Douglas L. Fraker3

Harrison Department of Surgical Research [B. W. E., C. M., D. L. F.] and Department of Radiation Oncology [A. V. K., S. M. H.], School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104


   ABSTRACT
Top
 ABSTRACT
INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Photodynamic therapy (PDT) involves light activation of a photosensitizer, resulting in oxygen-dependent, free radical-mediated cell death. Little is known about the efficacy of PDT in treating human sarcomas, despite an ongoing clinical trial treating i.p. sarcomatosis. The present study evaluates PDT treatment of a human sarcoma xenograft in nude mice and explores the mechanism of PDT-mediated antitumor effect. Athymic nude mice, 6–8 weeks of age, were s.c. injected with 5 x 106 cells of the A673 human sarcoma cell line. Tumors were allowed to grow to a diameter of about 10 mm. Photofrin (PF), 10 mg/kg, was injected by tail vein, and 24 h later, 630 nm light was delivered to the tumor with fluences of 50, 100, 150, or 300 J/cm2 at a fluence rate of 250 mW/cm2. To assess the efficacy of PDT in the treatment of sarcomas, photosensitizer uptake/retention studies and dose-response studies were performed. Studies carried out to determine the mechanism of tumor response included tumor temperature measurements before, during, and after treatment; tumor vascular perfusion studies with laser Doppler; electron microscopic analysis of tumor sections for vascular occlusion; and analysis of tumor cryosections for endothelial cell damage, apoptosis, and necrosis. At all time points of analysis, photosensitizer levels were greater in tumor than in muscle. Dose-response studies showed that at 100 J/cm2, five of six mice had a complete response to treatment, one of six had a partial response, and no deaths occurred. Temperature measurements indicated that thermal injury did not contribute to tumor response. Vascular perfusion studies demonstrated a significant reduction in blood flow as early as 6 h after PDT. Electron micrographs revealed erythrostasis in tumor microvessels starting as early as 2 h after treatment and complete occlusion of blood vessels by 12 h. Starting as early as 4 h after PDT, apoptosis first appeared in endothelial cells lining the occluded blood vessels and became more widespread at later time points. PDT is an effective treatment for this human sarcoma xenograft in nude mice. The mechanism of tumor destruction in this model appears to be vascular damage with initial apoptosis in tumor endothelial cells and delayed tumor cell apoptosis. This therapy may be valuable in the treatment of patients with sarcomatosis.


   INTRODUCTION
Top
 ABSTRACT
 INTRODUCTION
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
PDT4 is an antineoplastic treatment that involves the use of a photosensitizer, such as PF, the application of visible light of the wavelength specific for the photosensitizer, and the presence of oxygen leading to reactive oxygen species-mediated cytotoxicity to the treated cell. PF, the photosensitizer used in this study, is a partially purified derivative of hematoporphyrin that is activated by light at 630 nm. On absorbing a photon, PF is excited to a high energy singlet state. By an intersystem cross-over, the excited photosensitizer can undergo an electron spin conversion and yield a triplet sensitizer that can then be involved in a type I or type II photochemical reaction to produce damaging reactive oxygen species. (1) The photochemical reaction that occurs in the presence of oxygen is preferably the type II reaction.

There has been increasing enthusiasm for the use of PDT as a cancer treatment for surface malignancies with reports that hematoporphyrin derivative (2) and some second-generation photosensitizers (3 , 4) are selectively retained in malignant tissues. The mechanism for tumor responses to PDT in vivo has been studied (4, 5, 6, 7, 8, 9, 10) . Direct tumor cell kill, vascular damage, and inflammatory responses have all been shown to contribute to tumor destruction. A large portion of PF-mediated PDT damage to tumors in vivo has been shown to be related to vascular damage (5 , 9 , 11) . PF-mediated PDT causes a reduction in blood flow in tumors and normal tissue that is associated with vasoconstriction of arterioles and thrombosis of venules (12) , as well as erythrocyte aggregation and stasis (13, 14, 15, 16) .

Studies evaluating the mode of cell death after PDT in vivo have shown evidence of both apoptosis and necrosis (3 , 17 , 18) . The interplay of the direct tumor cell cytotoxicity and vascular effects of PDT and the induction of either necrosis or apoptosis within a tumor is complicated and under active investigation (19 , 20) . Insights into the mechanisms of tumor response and into the mode of cell death after PDT, especially in human tumors, may lead to ways to maximize the efficacy of this treatment.

One potential application of PDT is to treat the lining of the peritoneal cavity in patients with diffuse intraabdominal malignancies. Patients with intraabdominal and retroperitoneal sarcomas often develop diffuse i.p. spread or sarcomatosis without any evidence of distant spread. There is no effective treatment for sarcomatosis using standard surgical techniques, radiation therapy, or chemotherapy. Even when all gross disease is excised, these patients are destined to have recurrent tumor due to i.p. spreading of disease. Although preclinical studies have demonstrated the effectiveness of PDT in treating a variety of murine tumors including sarcomas (21, 22, 23) , little is known about the treatment of human sarcomas in preclinical models, despite the fact that the results of two clinical trials have been reported treating sarcomas (24 , 25) . Also, in our institution, there is an ongoing clinical trial to treat patients with i.p. sarcomatosis (4) . Preclinical models assessing the response of human sarcomas to PDT could potentially be used to optimize treatment protocols.

The present study, therefore, focuses on the effectiveness of PF-mediated PDT in treating human A673 sarcoma xenografts in nude mice. The selectivity of PF in tumor tissue compared with normal tissues, the mechanism of tumor response, and the mode of tumor cell death are also explored.


   MATERIALS AND METHODS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Animals, Tumor Production, and PF Injection.
Athymic nude mice (Harlan Sprague Dawley, Indianapolis, IN), 6–8 weeks of age, received s.c. injections of 5 x 106 cells of the human A673 sarcoma cell line (American Type Culture Collection, Bethesda, MD). The tumors were placed in the flank and were allowed to grow until they were ~10 mm in diameter. PF (a generous gift from QLT Phototherapeutics, Inc., Vancouver, British Columbia, Canada) was dissolved in 5% dextrose at a concentration of 1 mg/ml and injected by tail vein at a dose of 10 mg/kg.

Photosensitizer Uptake/Retention Measurements.
Mice were anesthetized, and tumor, muscle, skin, and serum were harvested at 12, 24, and 48 h after injection of PF. Samples from three mice were analyzed for PF levels per time point using an HPLC assay (26) that was modified in our laboratory. Briefly, tissue was kept in the dark at -80°C until analysis of drug concentration. Tissue, 50–100 mg, was dissolved in 1 ml of Solvable (DuPont, Boston, MA) and left overnight in the dark at 50°C. The samples were neutralized to pH 8 with acetic acid. One hundred µl of the sample were analyzed for each tissue. The intensity of the signal of PpIX was measured by HPLC using a C18 reverse phase column. The PpIX signal was chosen due to its higher retention time on the column. Also, a complete separation of PpIX signal from other peaks made it relatively easy to compare with the standard. Seventy % methanol in 10 mM sodium phosphate (pH 7.4) was used as the buffer. Concentrations of PpIX were determined from a standard curve and expressed as µg/g tissue weight. The intensity of PpIX signal was found to be linear with respect to PF concentration within a relatively wide range (1 ng/g tissue to 100 µg/g tissue), with a high correlation coefficient of 0.999. Because the levels of endogenous PpIX was below the limit of detection of the assay (<0.05 µg/g tissue), the values obtained for PpIX levels from the PF-containing tissues were used directly without subtraction of background. The tissues from one mouse that did not receive PF were used as negative controls. To determine whether the PF selectivity in tumor tissue was characteristic of the A673 tumor alone, PF levels were similarly measured in two other human sarcoma tumors, SK-ES-1 and SK-LMS-1.

PDT Efficacy Studies.
Nude mice received 3 Gy {gamma}-irradiation to improve tumor take 1 to 3 days before injection of A673 cells (5 x 106 cells) into the s.c. space in the flank. Mice were injected with PF (10 mg/kg) when tumors were ~10 mm in diameter. Control mice were injected with 5% dextrose using a similar volume as PF injections. Light was delivered 24 h after drug injection using a KTP-Yag pumped PDT dye laser (Laserscope model XP, San Jose, CA) at 630 nm with a fluence rate of 250 mW/cm2 and a Microlens optical fiber (Rare Earth Medical, West Yarmouth, MA). Mice used for dose-response studies received 50, 100, 150, or 300 J/cm2 (n = 6 for each group except 300 J/cm2, where n = 5). There were three control groups: (a) no PF, no light; (b) PF, no light; and (c) no PF, light at either 50, 100, 150, or 300 J/cm2 (n = 3 for each group).

Mechanism Studies.
Mice used for temperature measurements, Doppler flow studies, histological analyses, and apoptosis assays received PDT with 100 or 150 J/cm2, or light only at 100 or 150 J/cm2. Tumor response to PDT was categorized as "no response" if tumors continued to grow posttreatment, as "partial response" if tumors were <75% of pretreatment size, and as "complete response" if no tumor was visible. Tumors were categorized as a "recurrence" if they regrew after an initial response to PDT, which lasted for a minimum of 10 days after treatment.

Temperature Measurements.
Physitemp Thermalert (model TH-8, Clifton, NJ) was used to make tumor temperature measurements. The thermal probe was inserted just off-center and mid-depth into each of the tumors, with the tip of the probe halfway into the tumor. Measurements in triplicate were made before treatment, during treatment at 5- and 10-min time points, and at 1 min after the completion of treatment (n = 3 in control and treatment groups). Control tumors were given dextrose and light at 150 J/cm2, whereas experimental tumors were given PF and light at 150 J/cm2.

Tissue Perfusion/Flow Analysis.
Laser Doppler (Periflux 4001 Master; Permed, New York, NY) measurements of microvascular perfusion were made using a dental probe with 0.25-mm fiber separation. Measurements were obtained on three mice receiving light only, and eight mice receiving PDT (PF and light), at preillumination, 6, 12, 18, and 24 h after treatment. Light fluence used was 150 J/cm2. Five measurements at different sites on the tumors were made per mouse per time point. The highest and lowest measurements were discarded, and the remaining three were averaged. Measurements were also made in three tumors in dead mice. The average of the readings from the dead mice was considered the "no flow" reading and was subtracted from the average measurement of each mouse at each time point. The average of each time point was recorded as a proportion of the pretreatment perfusion for each individual mouse. These values were then averaged by treatment group to determine the relative flow of each group at each time point.

Tissue Harvesting and Storage for Electron Microscopy, Blood Vessel Staining, Apoptosis Assays, and H&E Staining.
Mice were sacrificed before treatment and at 2, 4, 8, 12, 18, 24, and 36 h after treatment (light-only group, n = 1; PDT group, n = 2; for each time point). Tissue for electron microscopy was fixed in 2% gluteraldehyde in 0.1 M sodium cacodylate buffer (pH 7.4) and kept at 4°C for 18 h. Tissue for H&E staining, blood vessel immunostaining, and apoptosis assays was frozen in OCT (Tissue-Tek) and kept at -80°C until analysis.

Electron Microscopy.
Fixed tissues were embedded in Epon 812 (EM Sciences, Fort Washington, PA), sectioned, and stained by standard techniques carried out at the Biomedical Imaging Core facility, Department of Pathology and Laboratory Medicine, at the University of Pennsylvania.

Blood Vessel Immunostaining.
Cryopreserved tumor tissue sections were immunostained with rat anti-murine PECAM antibody (a generous gift from Dr. Steven Albelda, University of Pennsylvania, Philadelphia, PA) using the ABC Elite kit and Vector VIP Peroxidase Substrate kit (Vector Labs, Burlingame, CA). The slides were viewed and photographed under a light microscope at x 100.

Apoptosis Assays.
Apoptosis assays were performed by the TUNEL assay using the In Situ Cell Death Detection kit (Boehringer Mannheim, Indianapolis, IN). The slides were viewed and photographed under a fluorescence microscope at x200.

Double Labeling for Blood Vessels and Apoptosis.
Cryopreserved tissue sections were fixed in cold acetone for 5 min and permeabilized using cold 0.1% Triton X-100 in 0.1% sodium acetate on ice for 2 min. Labeling for blood vessels was carried out using the above-mentioned anti-PECAM antibody in combination with anti-rat IgG Texas red for blood vessel staining. Apoptosis assays were carried out using the In Situ Cell Death Detection kit (Boehringer Mannheim). The sections were viewed and photographed under a fluorescence microscope at x100 using appropriate filters for Texas red or FITC.

H&E Staining of Tissue Sections for Necrosis.
H&E staining was carried out by standard methods at the Cell Morphology Core, Institute for Human Gene Therapy, University of Pennsylvania. The sections were visually scored for extent of necrosis in the tumors and photographed by bright field microscopy at x 150.

Statistics.
Statistical analysis of PF uptake/retention data, tumor temperature measurements, and laser Doppler flow measurements was performed using the Graphpad Instat computer software (version 3.0 for Windows NT). Values were compared using the unpaired Student’s t test with Welch correction. Statistical significance was assumed if the two-tailed P value was <0.05.


   RESULTS
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Photosensitizer Measurements.
PF levels were greater in tumor than in muscle at all time points studied (Fig. 1)Citation . This difference was statistically significant (P = 0.01) at 12 h. The ratio of mean tumor PF levels to mean muscle levels at 12 h was 1.12:0.26. PF levels in skin were greater than in tumor at all time points studied (data not shown), with the greatest difference occurring at 12 h (mean tumor, 1.12 µg/g tissue; mean skin, 1.69 µg/g tissue).



View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. HPLC analysis of uptake/retention of Photofrin II by tumor(), muscle({blacksquare}), and serum({square}). A673 human sarcoma cells were s.c. injected into nude mice, and tumors were allowed to grow until they were ~10 mm in diameter. Photofrin II (10 mg/kg) dissolved in 5% dextrose was injected by tail vein; mice were anesthetized, and tumor, muscle, and serum were harvested at 0, 12, 24, and 48 h after injection and analyzed by HPLC for PpIX concentrations expressed as µg/g tissue. Values in the graph represent mean values; bars, SE. Uptake by tumor was more than muscle at all time points.

 
To determine whether the PF selectivity in tumor tissue was characteristic of the A673 tumor, PF levels were measured in two other human sarcoma tumors, SK-ES-1 and SK-LMS-1 (data not shown). SK-ES-1-derived tumors showed statistically significant greater PF levels in tumor compared with muscle at both 12 and 24 h after drug injection (tumor, 0.53 and 0.58 µg/g tissue at 12 and 24 h, respectively; muscle, 0.2 and 0.23 µg/g at 12 and 24 h, respectively). The SK-LMS-1-derived tumors did not show a statistically significant difference between tumor and muscle at 12, 24, or 48 h, although the absolute measurements of PF were always greater in tumor. The mean absolute levels of PF in the A673, SK-ES-1, and SK-LMS-1 tumors at 12 h were 1.129, 0.52884, and 0.56283 µg/g tissue, respectively.

PF-mediated PDT Efficacy.
Complete tumor responses were observed in five of six mice in the 50 and 100 J/cm2 light fluence groups (Table 1)Citation . Partial tumor response was observed in one of six mice in each of these groups. In the complete responders, tumor regrowth occurred by 11 days after treatment in the 50 J/cm2 group, by 19 days in the 100 J/cm2 group, and by 21 days in the 150 J/cm2 group. Tumors and mice were observed for a period of 60 days after treatment. Regrowth was observed in a greater number of mice receiving lower fluences (50 or 100 J/cm2). The surviving mice at 150 J/cm2 had no recurrence out to 60 days in 66% of the cases.


View this table:
[in this window]
[in a new window]

  		Table 1 Summary of gross tumor and whole animal responses to PDT at 50, 100, 150, and 300 J/cm2 light doses

 
The average tumor size increased marginally on day 1 after light exposure in mice treated with 50 and 100 J/cm2 but was unchanged in mice treated with 150 J/cm2 (data not shown). By day 2 after light treatment, tumor size decreased rapidly at all fluences. The tumors became dusky and edematous 3–6 h after light treatment. An eschar developed after 2 days (Fig. 2)Citation .



View larger version (48K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Time course of gross tumor response to PDT. A673 human tumors were grown in nude mice up to a size of ~10 mm in diameter. Photofrin II (10 mg/kg) dissolved in 5% dextrose was injected by tail vein, and the tumors were exposed to light of 630 nm at 100 J/cm2 exactly 24 h later. Upper panel, response of control tumors injected with 5% dextrose; lower panel, response of Photofrin II-injected tumors. The PDT-treated tumors appear dusky 3–6h after light treatment and progressed to eschar over the course of 2–4 days.

 
There was increasing mortality observed with increasing fluence (Table 1)Citation . Death associated with PDT occurred within 1–5 days after treatment. Necropsies were performed on mice that suffered treatment-related death. In some of these cases, death appeared to be due to necrosis of bowel deep to the site of light treatment. In other cases, no cause of death could be identified. Of the three mice that survived a dose of 150 J/cm2, all showed a complete response to treatment (no tumor visible or palpable).

Mechanism of Tumor Cell Kill.
To determine the mechanism of tumor response, tumor temperature measurements and tissue perfusion studies were performed before treatment, during PDT, and after treatment. Electron micrographs of PDT-treated and control tumor sections were analyzed for vascular occlusion, and photomicrographs of cryopreserved tissue sections were immunostained for blood vessels and evaluated for apoptosis histologically. PDT-treated and control tumor sections were also scored for necrosis.

A slight temperature rise of ~4°C was measured after the initiation of PDT (Fig. 3)Citation . No significant difference (P = 0.974) in tumor temperature between control and treatment groups was noted before, during, or after treatment at a light fluence of 150 J/cm2. Maximal tumor temperature was <37°C in all mice during light treatment, and the temperature decreased rapidly after light treatment was complete. These results suggest that the tumor response was not due to thermal injury.



View larger version (11K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 3. Tumor temperature measurements of control [dextrose, light at 150 J/cm2 ({blacksquare})] or PDT-treated tumors [PF, light at 150 J/cm2 ({diamond})] before (at 0 min), during (at 5 and 10 min), and after treatment (at 11 min, light turned off). Temperature measurements showed no difference between control and treatment groups. All mice were hypothermic before treatment. The tumor temperature increased to a maximum of <37°C by the end of treatment and returned to pretreatment levels within 1 min after the laser was turned off. Bars, SE.

 
Laser-Doppler studies of tumor vascular blood flow demonstrated a very significant reduction (P = 0.0074) in blood flow as early as 6 h after PDT compared with control groups (Fig. 4)Citation at a fluence of 150 J/cm2. Perfusion remained decreased up to 60 h after treatment (data not shown), consistent with the gross appearance of tumors (Fig. 2)Citation . Blood flow in the control tumors was generally stable over time.



View larger version (14K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 4. Flow measurements using laser-Doppler in control [dextrose, light at 150 J/cm2({blacksquare})] and PDT-treated tumors({diamondsuit}). Flow measurements were made before treatment and at 6, 12, 18, and 24 h after treatment. Compared with the control tumors, PDT-treated tumors showed decreased flow by 6 h that persisted even at 24 h after treatment. Bars, SE.

 
Electron micrographs of tumor sections revealed erythrostasis starting as early as 2 h after light treatment in mice with PDT-treated tumors (Fig. 5)Citation . This change in vascular appearance was a consistent histological finding in PDT-treated tumors and persisted through all later time points studied. Two h after PDT, tumor cells and endothelial cells appeared normal and viable. After 12 h, however, the tumor cell nuclei in the immediate vicinity of the blood vessels showed condensed and abnormally fragmented chromatin. Tumor cell nuclei at a greater distance from the blood vessel appeared normal at this time point. Most tumor cells were clearly pyknotic in all locations by 36 h.



View larger version (165K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 5. Electron micrographs of tissue sections of control and PDT-treated tumors. A, 2-h control; B, 2 h after PDT; C, 12-h control; D, 12 h after PDT. A and C, normal blood vessels (bv), endothelial cells (ec), and tumor cells (tc). Erythrostasis in the blood vessel is evident as early as 2 h after PDT (B). The tumor and endothelial cells appear normal at this time point. At 12 h after-PDT (D), the blood vessel appears further occluded, and the tumor cell nuclei in the immediate vicinity of the blood vessel appear fragmented and condensed. x4320.

 
Anti-PECAM staining of control and PDT-treated tumor sections revealed that PDT caused a disruption of the endothelial lining of blood vessels (Fig. 6)Citation . Tumor sections labeled for apoptotic cells using the TUNEL assay (Fig. 7)Citation demonstrated little or no apoptosis in the control specimens receiving no treatment, light only, or sensitizer. However, in specimens from PDT-treated tumors, progressively increasing numbers of apoptotic cells were visible starting from 4 h after PDT. At this early time point, apoptotic cells were patchy and few in number, but by 36 h there was widespread apoptosis. In PDT-treated tumor sections that were double-labeled for blood vessels and apo-ptosis, it appeared that the initial apoptotic cells were tumor endothelial cells (Fig. 8)Citation .



View larger version (136K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 6. Photomicrographs of control (left panels) and PDT-treated (right panels) cryopreserved tumor sections immunostained for blood vessels using an anti-PECAM antibody. Tissue sections of control tumors at 4, 18, and 36 h (A, C, and E, respectively) show normal blood vessels, whereas the PDT-treated tumors at 4, 18, and 36 h after treatment (B, D, and F, respectively) show a progressive disruption of the endothelial layer of blood vessels. x100.

 


View larger version (166K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 7. Photomicrographs of control (left panels) and PDT-treated (right panels) of cryopreserved tumor sections labeled for apoptosis using the TUNEL assay. Tissue sections of control tumors at 4, 18, and 36 h (A, C, and E, respectively) show little or no apoptotic cells. PDT-treated tumor sections at 4, 18, and 36 h (B, D, and F, respectively) show a progressively increasing number of apoptotic cells with increasing time after PDT.

 


View larger version (119K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 8. Photomicrographs of double-labeled control and PDT-treated tumor tissue sections for blood vessels (left panels) and apoptosis (right panels). Tissue sections were immunofluorescently labeled for blood vessels using a rat anti-mouse PECAM antibody and anti-rat IgG Texas red and later labeled for apoptosis using the TUNEL assay. The double-labeled sections show that at the early time points, 4 h (A and B), 8 h (C and D), and 12 h (E and F) after PDT, apoptotic cells first appear around blood vessels.

 
Histological analysis of tissue sections by H&E staining (data not shown) revealed patchy areas of necrosis in all sections (control and treatment) interspersed within viable tumor cell areas. Although beginning at 12 h after PDT, more abundant patches of necrosis appeared within the tumors of the PDT-treated mice; the patches were small, unconnected, and did not appear to increase in size. Necrosis, although certainly contributing to some tumor destruction, does not appear to be the primary cause of cell death after PDT in this model.


   DISCUSSION
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
PDT therapy is an approved treatment or under experimental clinical investigation for a variety of malignancies and premalignant conditions including head and neck cancers (27 , 28) , lung cancer (29 , 30) , mesothelioma (31 , 32) , and esophageal cancer (33) . Clinically, there has been some application in the treatment of intraabdominal sarcomas (24 , 25) . However, little preclinical data exist using PDT to treat this histology. Although the demonstration of efficacy of a cancer treatment in preclinical models does not translate into clinical efficacy, most investigators would agree that the absence of such preclinical efficacy studies casts serious doubts about a treatment for a particular cancer.

In an ongoing Phase II clinical trial of PDT for diffuse i.p. malignancies at the University of Pennsylvania, approximately one-half of the patients treated have sarcomatosis. Because of these referral patterns and the need to develop new approaches for this intractable condition, we evaluated the efficacy of PDT against human sarcoma for the first time in a preclinical model.

The data presented in this study demonstrate that PF-mediated PDT can lead to complete eradication of the human A673 sarcoma xenograft in nude mice. An initial complete response was achieved in five of six mice at light fluences ranging from 50 to 150 J/cm2. A sustained complete response was greatest and regrowth of tumor was the lowest at the higher total light fluences, demonstrating a dose-response relationship to PF-mediated PDT. The treatment responses in this study were achieved with relatively high fluence rates (250 mW/cm2). It has been shown in some experimental tumor models that higher fluence rates lead to a greater depletion of oxygen during the administration of light and, therefore, to reduced PDT efficacy (33, 34, 35, 36, 37) . Although it is encouraging that positive treatment outcomes were the results, even with the relatively high fluence rate used in this study, it is likely that better treatment outcomes are possible with lower fluence rates. The complete responses seen at 250 mW/cm2 would indicate that this tumor is relatively well oxygenated such that oxygen consumption at the relatively high fluence rate used in this study did not limit the response.

One of the major reasons for enthusiasm surrounding the use of PDT in cancer treatment is the reported selectivity of many of the photosensitizers for tumor compared with normal tissues (2, 3, 4) . In this study, normal tissue levels of PF were measured with an HPLC assay. This assay method allows for the determination of the concentration of individual components of PF and also allows for their separation from other porphyrin compounds present in tissue. Also, the sensitivity of the HPLC assay is very high, and the range of concentrations that can be determined by this method is higher than other known methods (from 1 ng/g tissue to 100 µg/g tissue). Moreover, the more commonly used fluorescence method requires subtraction of endogenous tissue fluorescence, which significantly reduces the ability to measure photosensitizer levels at lower concentrations. As stated in "Materials and Methods," the level of endogenous PpIX is below the limit of detection of this assay; therefore, it does not need to be subtracted from the measured value. In this study, a greater concentration of photosensitizer was measured in the A673 tumor compared with the surrounding muscle tissue. These results are similar to earlier findings (2 , 4 , 19,) . The mechanism of preferential retention of photosensitizers in tumor compared with other tissues has been a topic of much study (4 , 38) . Many factors have been explored, including increased lipoprotein receptors (especially low-density lipoprotein) on tumors, uptake of sensitizers by tumor-associated macrophages, and an altered tumor microenvironment.

Mechanisms of PDT-mediated cytotoxicity in the A673 tumor were investigated by various functional and histological techniques over the posttreatment time period. Temperature measurements show that thermal injury is not likely to be a significant factor in tumor response. Both flow studies and a variety of histological studies suggest that the primary effect of PDT in this model appears to be vascular damage. Damage to the vasculature with PF-mediated PDT is known to be an important component of tumor response in other preclinical models (13 , 20) , and our results confirm this. The kinetics of the vascular response in the present model of a human sarcoma xenograft agree with the previous reports on tumors of different histologies. Electron micrographs of tissue sections demonstrate occlusion of the tumor blood vessels with associated erythrostasis as early as 2 h after tumor illumination. The initial laser Doppler studies were performed 6 h after PDT and, at that early time point, showed significant loss of blood flow. Decrease in blood flow after PF-mediated PDT has also been shown in other tumor systems (39) . On the basis of earlier electron microscopy results, flow is likely to be decreased and should be one of the initial events in this model. PF-mediated PDT also progressively affected the integrity of the endothelial lining of blood vessels, as shown by photomicrographs of tumor tissue sections stained with an anti-PECAM antibody. The precise molecular reasons for these findings are not clear, but all results point to an occlusion of tumor vasculature at the initiation of the tumor response.

With increasing time after tumor illumination, endothelial cell and tumor cell apoptosis was demonstrated in tissue sections. One potential explanation for this is that blood vessel occlusion and subsequent endothelial damage lead to tumor hypoxia. Hypoxia has been shown to lead to apoptosis through a variety of mechanisms, including changes in p53 protein level and caspase activation associated with cytochrome c release from mitochondria (40, 41, 42) . The electron micrographs and immunohistochemical staining in this study support the hypothesis that blood vessel occlusion triggered apoptosis in the surrounding tumor tissue. Apoptotic cells appeared later (at 4–12 h) than vessel occlusion and erythrostasis (at 2 h after PDT) and was initiated in the immediate vicinity of occluded blood vessels at the early time points after PDT. This early erythrostasis and vessel occlusion may be due to the triggering of apoptotic pathways, specifically in the tumor endothelium. Tumor endothelium, because of its higher oxygen content and/or greater PF level, may be more susceptible to PDT-induced apoptosis and may be the primary target for the response seen in this preclinical model. Necrosis in this tumor model, although present, appears to be a less significant mode of cell death than apoptosis in response to PF-mediated PDT.

Successful treatment of the human A673 sarcoma xenograft was demonstrated in this study with PF-mediated PDT. Greater levels of photosensitizer were measured in tumor compared with surrounding muscle tissue. The mechanism of the tumor response to PDT appears to be vascular damage with subsequent vascular stasis and occlusion. It is postulated that hypoxia induced by PDT leads to apoptosis of the surrounding tumor and contributes substantially to the tumor response. Additional studies to optimize the response to PDT, including an evaluation of fluence rate effects and photosensitizers with greater tumor selectivity, would be warranted. PDT is a reasonable treatment to evaluate in patients with sarcoma with the primary need as an adjunct therapy after debulking for i.p. disease.


   ACKNOWLEDGMENTS
 
We thank Carmen Rodriguez for technical assistance with the laser. We are also grateful to Drs. Matt Van De Rijn and Thomas Lawton for help with analysis of electron micrographs, to Dr. Michael Goldschmidt for help with visual scoring of histological sections for necrosis, and to Dr. James F. Sanzo for help with electron micrograph composite. We also thank Dr. Theresa Busch for suggestions in the preparation of the manuscript. We acknowledge Sara Kutney, Cyrus Khorrami, and Victor Lai for general laboratory support.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported in part by the Georgene S. Harmelin Endowment Fund. Back

2 These authors contributed equally to this work. Back

3 To whom requests for reprints should be addressed, at Hospital of the University of Pennsylvania, 4th Floor Silverstein Building, 3400 Spruce Street, Philadelphia, PA 19104. Phone: (215) 662-7866; Fax: (215) 662-7476. Back

4 The abbreviations used are: PDT, photodynamic therapy; PF, Photofrin; HPLC, high-performance liquid chromatography; PpIX, protoporphyrin IX; TUNEL, terminal deoxynucleotidyltransferase-mediated nick end labeling. Back

Received 3/11/99. Accepted 7/ 7/99.


   REFERENCES
Top
 ABSTRACT
 INTRODUCTION
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Pass H. I. Photodynamic therapy in oncology: mechanisms and clinical use. J. Natl. Cancer Inst., 85: 443-456, 1993.[Abstract/Free Full Text]
  2. Gomer C. J., Dougherty T. J. Determination of [3H]- and [14C]hematoporphyrin derivative distribution in malignant and normal tissue. Cancer Res., 39: 146-151, 1979.[Abstract/Free Full Text]
  3. Woodburn K. W., Fan Q., Miles D. R., Kessel D., Luo Y., Young S. W. Localization and efficacy analysis of the phototherapeutic lutetium texaphyrin (PCI-0123) in the murine EMT6 sarcoma model. Photochem. Photobiol., 65: 410-415, 1997.[Medline]
  4. Dougherty T. J., Gomer D. J., Henderson B.W., Jori G., Kessel D., Korbelik M., Moan J., Peng Q. Photodynamic therapy. J. Natl. Cancer Inst., 90: 889-905, 1998.[Abstract/Free Full Text]
  5. Clan W. S., Brasseur N., La Madeleine C., van Lier J. E. Evidence for different mechanisms of EMT-6 tumor necrosis by photodynamic therapy with disulfonated aluminum phthalocyanine or Photofrin. Anticancer Res., 16: 1887-1892, 1996.[Medline]
  6. Henderson B. W., Waldow S. M., Mang T. S., Potter W. R., Malone P. B., Dougherty T. J. Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy. Cancer Res., 45: 572-576, 1985.[Abstract/Free Full Text]
  7. Kessel D., Woodburn K., Henderson B. W., Chang C. K. Sites of photodamage in vivo and in vitro by a cationic porphyrin. Photochem. Photobiol., 62: 875-881, 1995.[Medline]
  8. McMahon K. S., Wieman T. J., Moore P. H., Fingar V. H. Effects of photodynamic therapy using mono-L-aspartyl chlorin e6 on vessel constriction, vessel leakage, and tumor response. Cancer Res., 54: 5374-5379, 1994.[Abstract/Free Full Text]
  9. van Geel I. P., Oppelaar H., Oussoren Y. G., Stewart F. A. Changes in perfusion of mouse tumours after photodynamic therapy. Int. J. Cancer, 56: 224-228, 1994.[Medline]
  10. Fingar V. H., Wieman T. J., Karavolos P. S., Doak K. W., Ouellet R., van Lier J. E. The effects of photodynamic therapy using differently substituted zinc phthalocyanines on vessel constriction, vessel leakage, and tumor response. Photochem. Photobiol., 58: 251-258, 1993.[Medline]
  11. Henderson B. W., Dougherty T. J. How does photodynamic therapy work?. Photochem. Photobiol., 55: 145-157, 1992.[Medline]
  12. Reed M. W. R., Wieman T., Schuschke D. A., Teng M. T., Miller F. N. A comparison of the effects of photodynamic therapy on normal and tumor blood vessels in the rat microcirculation. Radiat. Res., 119: 542-552, 1989.[Medline]
  13. Fingar V. H. Vascular effects of photodynamic therapy. J. Clin. Laser Med. Surg., 14: 323-328, 1996.[Medline]
  14. Wieman T. J., Mang T. S., Fingar V. H., Hill T. G., Reed M. W., Corey T. S., Nguyen V. Q., Render E. R. Effect of photodynamic therapy on blood flow in normal and tumor vessels. Surgery, 104: 512-517, 1988.[Medline]
  15. Fingar V. H., Wieman T. J., Wiehle S. A., Cerrito P. B. The role of microvascular damage in photodynamic therapy: the effect of treatment on vessel constriction, permeability, and leukocyte adhesion. Cancer Res., 52: 4914-4921, 1992.[Abstract/Free Full Text]
  16. Orenstein A., Nelson J. S., Liaw L. H., Kaplan R., Kumel S., Berns S. W. Photochemotherapy of hypervascular dermal lesions: a possible alternative to photochemical therapy?. Lasers Surg. Med., 10: 334-343, 1990.[Medline]
  17. Zaidi S. I., Oleinick N. L., Zaim M. T., Muktar H. Apoptosis during photodynamic therapy-induced ablation of RIF-1 tumors in C3H mice: electron microscopic, histopathologic and biochemical evidence. Photochem. Photobiol., 58: 771-776, 1993.[Medline]
  18. Webber J., Luo Y., Crilly R., Fromm D., Kessel D. An apoptotic response to photodynamic therapy with endogenous protoporphyrin in vivo. J. Photochem. Photobiol., 35: 209-211, 1996.
  19. Oleinick N. L., Evans H. H. The photobiology of photodynamic therapy: cellular targets and mechanisms. Radiat. Res., 150: S146-S156, 1998.
  20. Peng Q., Moan J., Nesland J. M. Correlation of subcellular and intratumoral photosensitizer localization with ultrastructural features after photodynamic therapy. Ultrastruct. Pathol., 20: 109-129, 1996.[Medline]
  21. Tochner Z., Mitchell J. B., Smith P., Harrington F., Glatstein E., Russo D., Russo A. Photodynamic therapy of ascites tumours within the peritoneal cavity. Br. J. Cancer, 53: 733-736, 1986.[Medline]
  22. Cincotta L., Foley J. W., Cincotta A. H. Phototoxicity, redox behavior, and pharmacokinetics of benzophenoxazine analogues in EMT-6 murine sarcoma cells. Cancer Res., 53: 2571-2580, 1993.[Abstract/Free Full Text]
  23. Cincotta L., Szeto D., Lamprox E., Hasan T., Cincotta A. H. Benzophenothiazine and benozoporphyrin derivative combination phototherapy effectively eradicates large murine sarcomas. Photochem. Photobiol., 63: 229-237, 1996.[Medline]
  24. Nambisan R. N., Karakousis C. P., Holyoke E. D., Dougherty T. J. Intraoperative photodynamic therapy for retroperitoneal sarcomas. Cancer (Phila.), 61: 1248-1252, 1988.[Medline]
  25. Sindelar W. F., Sullivan F. J., Abraham E., Delaney T. F., Smith P. D., Friauf G. F., Smith B., Ohnieff P. O. Intraperitoneal photodynamic therapy shows efficacy in Phase I trial. Proc. Am. Soc. Clin. Oncol., 14: 477-, 1995.
  26. Bellnier D. A., Greco W. R., Parsons J. C., Oseroff A. R., Kuebler A., Dougherty T. J. An assay for the quantitation of Photofrin in tissues and fluids. Photochem. Photobiol., 66: 237-244, 1997.[Medline]
  27. Biel M. A. Photodynamic therapy and the treatment of head and neck cancers. J. Clin. Laser Med. Surg., 14: 239-244, 1996.[Medline]
  28. Grant W. E., Speight P. M., Hopper C., Bown S. G. Photodynamic therapy: an effective, but non-selective treatment for superficial cancers of the oral cavity. Int. J. Cancer, 71: 937-942, 1997.[Medline]
  29. Cortese D. A., Edell E. S., Kinsey J. H. Photodynamic therapy for early stage squamous cell carcinoma of the lung. Mayo Clin. Proc., 72: 595-602, 1997.[Abstract]
  30. McCaughan J. S., Williams T. E. Photodynamic therapy for endobronchial malignant disease: a prospective fourteen-year study. J. Thorac. Cardiovasc. Surg., 114: 940-947, 1997.[Abstract/Free Full Text]
  31. Mostal T. L., Dougherty T. J., Urschel J. D., Antowiok J. G., Regal A. M., Driscoll D. L., Tahiti H. Operation and photodynamic therapy for pleural mesothelioma: 6-year follow-up. Ann. Thorac. Surg., 66: 1128-1133, 1998.[Abstract/Free Full Text]
  32. Pass H. I., Delaney T. F., Tochner Z., Smith P. E., Temeck B. K., Pogrebniak H. W., Kranda K. C., Russo A., Friauf W. S., Cole J. W., Mitchell J. B., Thomas G. Intrapleural photodynamic therapy: results of a Phase I trial. Ann. Surg. Oncol., 1: 28-37, 1994.[Medline]
  33. Lightdale C. J., Heier S. K., Marcon N. E., McCaughan J. S., Gerdes H., Overholt B. F., Sivak M. V., Stiegmann G. V., Nava H. R. Photodynamic therapy with porfimer sodium versus thermal ablation therapy with Nd:YAG laser for palliation of esophageal cancer: a multicenter randomized trial. Gastrointest. Endosc., 42: 507-512, 1995.[Medline]
  34. Sitnik T. M., Hampton J. A., Henderson B. W. Reduction of tumour oxygenation during and after photodynamic therapy in vivo: effects of fluence rate. Br. J. Cancer, 77: 1386-1394, 1998.[Medline]
  35. Sitnik T. M., Henderson B. W. The effect of fluence rate on tumor and normal tissue responses to photodynamic therapy. Photochem. Photobiol., 67: 462-466, 1998.[Medline]
  36. Robinson D. J., de Bruijn H. S., van der Veen N., Stringer M. R., Brown S. B., Star W. M. Fluorescence photobleaching of ALA-induced protoporphyrin IX during photodynamic therapy of normal hairless mouse skin: the effect of light dose and irradiance and the resulting biological effect. Photochem. Photobiol., 67: 140-149, 1998.[Medline]
  37. Foster T. H., Murant R. S., Bryant R. G., Knox R. S., Gibson S. L., Hilf R. Oxygen consumption and diffusion effects in photodynamic therapy. Radiat. Res., 126: 296-303, 1991.[Medline]
  38. Lin C. W. Selective localization of photosensitizers in tumors: a review of the phenomenon and possible mechanisms Kessel D. eds. . Photodynamic Therapy of Neoplastic Disease, : 79-101, CRC Press Boca Raton, FL 1990.
  39. Chan W. S., Brasseur N., la Madeleine C., van Lier J. E. Evidence for different mechanisms of EMT-6 tumor necrosis by photodynamic therapy with disulphonated aluminum phthalocyanine or Photofrin: tumor cell survival and blood flow. Anticancer Res., 16: 1887-1892, 1996.
  40. Riva C., Chauvin C., Pison C., Leverue X. Cellular physiology and molecular events in hypoxia-induced apoptosis. Anticancer Res., 18: 4729-4736, 1998.[Medline]
  41. Araya R., Uehara T., Nomura Y. Hypoxia induces apoptosis in human neuroblastoma SK-N-MC cells by caspase activation accompanying cytochrome c release from mitochondria. FEBS Lett., 439: 168-172, 1998.[Medline]
  42. Carmeliet P., Dor Y., Herbert J. M., Fukumura D., Brussellmans K., Dewerchin M., Neeman M., Bono F., Abramovitch R., Maxwell P., Koch C. J., Ratcliffe P., Moons L., Jain R. K., Callen D., Keshet E. Role of HIF-1{alpha} in hypoxia-mediated apoptosis, cell proliferation and tumor angiogenesis. Nature (Lond.), 394: 485-490, 1998.[Medline]



This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
S. Mitra, S. E. Cassar, D. J. Niles, J. A. Puskas, J. G. Frelinger, and T. H. Foster
Photodynamic therapy mediates the oxygen-independent activation of hypoxia-inducible factor 1{alpha}
Mol. Cancer Ther., December 1, 2006; 5(12): 3268 - 3274.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. M. Hahn, M. E. Putt, J. Metz, D. B. Shin, E. Rickter, C. Menon, D. Smith, E. Glatstein, D. L. Fraker, and T. M. Busch
Photofrin uptake in the tumor and normal tissues of patients receiving intraperitoneal photodynamic therapy.
Clin. Cancer Res., September 15, 2006; 12(18): 5464 - 5470.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Solban, S. K. Pal, S. K. Alok, C. K. Sung, and T. Hasan
Mechanistic Investigation and Implications of Photodynamic Therapy Induction of Vascular Endothelial Growth Factor in Prostate Cancer
Cancer Res., June 1, 2006; 66(11): 5633 - 5640.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
G. M. LaMuraglia, J. Schiereck, J. Heckenkamp, G. Nigri, P. Waterman, D. Leszczynski, and S. Kossodo
Photodynamic Therapy Induces Apoptosis in Intimal Hyperplastic Arteries
Am. J. Pathol., September 1, 2000; 157(3): 867 - 875.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Engbrecht, B. W.
Right arrow Articles by Fraker, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Engbrecht, B. W.
Right arrow Articles by Fraker, D. L.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online